Tbilisi: The Deputy Healthy Minister of Georgia, Tamar Gabunia noted “The most notable and important thing to consider is that the effect of Vosoritide on the kidney, liver and other organs is not known, in the medium or long-term perspectives.”
“The manufacturer states that the medication is characterized by serious side effects. “Most notable and significant is that its impact on the kidneys, liver and other organs is not known in the medium or long-term perspectives,” the deputy health minister said.
According to Tamar Gabunia, due to the lack of data regarding the medication, the developed countries of the world are being cautious about this issue to guarantee the safety of the patient.
As the Deputy Minister of Health noted, if by the end of September this year, the EU, even in several countries, is confirmed by the state to provide this medicine to patients, Georgia is ready, considering their best practice and responsibility, to take on its obligation unconditionally and start procedures for importing the medicine in Georgia.
“We consulted with the World Health Organization, which says the drug has not yet been recognised because it has been too little time lapse and the data is lacking.” We also had a consultation with the European Association of Rare Diseases.Â
Their recommendation was that we follow other countries’ experience, best practice so far, but they also confirmed their willingness to help us with this data. Their position is the same, it is still too early to implement the drug safely in the country and have more benefits than possible, something no one has data on yet. Our offer yesterday was about the fact that more time is needed”, – Tamar Gabunia said.
By its own definition, the Ministry of Health is ready to organize and finance the diagnosis, treatment, rehabilitation and all necessary procedures of children with acondroplasia, both in Georgia and abroad.
